2023 Addiction Medicine Review Course
The 2023 Addiction Medicine Review Course reviews the essentials of addiction treatment while incorporating current evidence-based practices in this everchanging field. This activity was recorded live August 30 - September 2, 2023.
Member $795 | Non-Member $1095
Target Audience
• Physicians in all medical fields seeking to build their expertise in the full spectrum of diagnosis and management of substance use disorders.
• Physicians preparing for The American Board of Preventive Medicine Addiction Medicine Board Examination.
• Physicians in the field who want a refresher course based on the latest clinical research.
• Any health care professionals, including but not limited to psychotherapists, nurses and drug abuse counselors, are involved in the treatment of patients with substance use disorders.
Learning Objectives
AFTER ATTENDING THIS CONFERENCE, PARTICIPANTS SHOULD BE ABLE TO:
• Reflect on key principles of addiction medicine as outlined by the American Board of Preventative Medicine
• Describe the pharmacology and physiological effects of major substances of abuse, including intoxication and withdrawal states, as well as associated health consequences
• Summarize basic epidemiology and diagnosis of major substance use disorders
• Outline current evidence-based pharmacological treatment and non-pharmacologic interventions for major substance use disorders
• Examine emerging evidence around novel treatments and approaches to alcohol and opioid withdrawal, and frontiers of harm reduction
Fentanyl Futures: Dynamics in supply, Use Patterns and Public Health Responses
Opioids & Fentanyl
Alcohol
Benzodiazepine-Sparing Protocol for Alcohol Withdrawal Panel
Stimulants
Co-occuring Mental Health Disorders
Treatments for ADHD in Susbstance Use Disorders Debate
Psychosocial Treatments
Spirituality Fireside Chats
Dopamine Fasting: An Early Intervention for Compulsive Overconsumption in the Digital Age
Adolescent Addiction Medicine Panel
Cannabis
Co-occuring Medical Presentations
Neurobiology
Sedative-Hypnotics
Pregnancy
Frontiers in Harm Reduction Panel
Ketamine in Buprenorphine Induction
Novel Ketamine Use in Addiction Medicine and Psychiatry
Nicotine
Ethics, Law, and Telehealth
Process Addiction
Arastou Aminzadeh, MD
Child and Adolescent Psychiatrist
BNI Treatment Center
Robert M. Anthenelli (he/him/his), MD
Professor of Psychiatry and Director, Pacific Treatment & Research Center @ UC San Diego
University of California, San Diego, School of Medicine
Raghu K. Appasani (he/him/his), MD
Integrative & Addiction Psychiatrist
Cullen Averill, MD
Emergency Medicine Physician
VA Loma Linda Healthcare System
Javier Ballester (he/him/his), MD
Addiction Psychiatrist
VA Salt Lake City
Leo Beletsky, JD MPH
Professor of Law and Health Sciences
UCSD Medical School/Northeastern
Christopher Blazes, MD
Associate Professor Dept of Psychiatry
OHSU
Maurice Byrd (he/him/his), M.S., LMFT
Director of Training and Business Operations
Harm Reduction Therapy Center
Gilmore Chung (he/him/his), MD
Director of Addiction Medicine
Venice Family Clinic
Dan Ciccarone (he/him/his), MD, MPH
Justine Miner Professor of Addiction Medicine
UCSF
Lucinda A. Grande (she/her/hers), MD
Partner
Pioneer Family Practice
Andrew A. Herring, MD
Chief of Addiction Medicine
Alameda Health System
Elizabeth F. Howell (she/her/hers), MD, MS
Professor of Psychiatry
University of Utah
Mitika Kanabar (she/her/hers), MD, MPH, FASAM, Dip ABLM
Physician Director of Education
Kaiser Permanente Antelope Valley
David Kan, MD, DFASAM
Private Practice of Psychiatry, Addiction Psychiatry and Forensic Psychiatry, Chief Medical Officer, Bright Heart Health
University of California, San Francisco
Waseem Khader, DO
Medical Director
Revive Pathway
Tipu Khan (he/him/his), MD, FAAFP, FASAM
Director of ADM and ADM Fellowship Director at Ventura County Medical Center; So. Cal. Medical Director for HealthRight360
Eve Lasswell (she/her/hers), PsyD
Assistant Clinical Professor
University of California San Diego
Anna Lembke, MD, FASAM
Director, Stanford University Addiction Medicine Fellowship and Chief, Stanford University Addiction Medicine Clinic
Stanford University School of Medicine
Barbara J. Mason (she/her/hers), PhD
Professor
The Scripps Research Institute
Julio Meza, MD
Addiction Medicine Fellowship Program Director
UCLA
Johanna O'Flaherty (she/her/hers), PhD
President/CEO
JF Recovery, LLC
Siddarth Puri (he/him/his), MD
Associate Medical Director of Prevention
Los Angeles County Department of Public Health, Substance Abuse Prevention and Control
Soma Snakeoil (she/her/hers), None
Executive Director/CoFounder
The Sidewalk Project
Christy Sutherland (she/her/hers), MD CCFP (AM) dABAM
Medical Director
PHS Community Services Society
Mason S. Turner (he/him/his), MD, DFASAM
Senior Medical Director for Behavioral Health
Intermountain Healthcare
Gerrit I. van Schalkwyk (he/him/his), MD
Psychiatrist
Naval Medical Center, San Diego
Jonathan Watson (he/him/his), MD
Physician
Orange County Jail
Cory Weissman, MD
Assistant Professor, Medical Director of Interventional Psychiatry
University of California San Diego, Department of Psychiatry
Alexander S. Young (he/him/his), MD, MSHS
Professor
UCLA
Tauheed Zaman, MD
UCSF and San Francisco VA Health Care System
San Francisco VA Medical Center
The California Society of Addiction Medicine is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians.
The California Society of Addiction Medicine designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 16.25 AMA Category 1
- 16.25 Attendance